A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
DRUG: Trastuzumab, Capecitabine and Cisplatin
Efficacy (Overall tumor response), Overall tumor response (responder/non-responder) which is a primary efficacy endpoint: is defined as the maximal response among confirmed cases of complete response (CR) or partial response (PR) determined by definite radiological assessment of target and nontarget lesions in accordance with RECIST criteria version 1.1., 2 years
progression free survival, Time from the start date of chemotherapy to the date of disease progression or death of any cause which comes first, 2 years|Duration of response, Time from the date of tumor response by RECIST version 1.1 to the date of disease progression, 2 years|Overall Survival, Time from the start date of chemotherapy to the date of death of any cause, 2 years|Time to disease progression, Time from the start date of chemotherapy to the date of disease progression, 2 years|Safety(Toxicity profile), Assessed by NCI CTCAE version 5.0, 2 years
3-weekly/ 1cycle treatment

* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks
* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)
* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1